At a joint session of the American College of Obstetricians and Gynecologists, and the Society for Academic Specialists in General Obstetrics and Gynecology, 2 physicians shared important updates in women’s health released during the COVID-19 pandemic.
Christine Isaacs, MD, professor of Obstetrics and Gynecology at Virginia Commonwealth University and Interim Chair in Richmond; and William M. Leininger, MD, from the Naval Medical Center in San Diego and assistant professor, Uniformed Services University in Bethesda, Maryland, discussed women’s health clinical updates, practical guidelines, and patient management tools, as well as educational resources to facilitate practice-based learning, in their session, “Our annual booster shot: clinical updates from ACOG-SASGOG at the 2022 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting in San Diego, California.
One of the first studies looked at in this session was the predictions of the vaginal birth after cesarean delivery (VBAC) calculator, with the aim to develop an accurate tool to predict VBAC, without inclusion of race and ethnicity. Results of this study showed that VBAC was more likely for women who were taller and had a prior vaginal birth; it was less likely for women who were older, were of heavier weight, had a prior cesarean delivery for arrest of dilation or descent, or had a history of chronic hypertension on meds.
The presenters then shared results from a systematic review of oral antihypertensives for non-severe pregnancy hypertension. The aims of this review included prevention of proteinuria/preeclampsia, fetal/newborn death, preterm birth, and NICU admission using these medications. Results from the meta-analysis of randomized trials of anti-hypertensives showed that all medications reduced the risks of severe hypertension by 30% to 70%, with the medication labetalol statistically better at decreasing proteinuria/pre-eclampsia and fetal/newborn death.
Additional updates included, among others:
--management of nonpalpable radiopaque contraceptive implant, which is FDA-approved for up to 3 years
--negative patient descriptors in electronic health records (results showing that Black patients had 2.54 times the odds of having a negative descriptor as White patients)
--a review of low-dose misoprostol for induction of labor, which proved that low-dose oral misoprostol to induce labor led to fewer cesarean deliveries, and oral dosing caused less hyperstimulation with fetal heart rate changes vs vaginal dosing
--a look at clothing, electrical devices, and surgical site infection, with evidence supporting glove change before abdominal cavity closure if visible soilage from bowel or intra-abdominal contents; no evidence showing covered arms during skin antisepsis decreases surgical site infections (SSIs); a lack of evidence for disinfection of electronic devices to prevent SSIs or clinician infection; and a lack of evidence between attire practices and SSI’s.
--notes from a systemic review between NSAIDs and perioperative bleeding (the meta-analysis showed no difference in NSAIDs vs non-NSAIDs in hematoma, return to the operating room for bleeding, or blood transfusion, with the conclusion being that NSAIDS should be encouraged as an adjunct or replacement for opioids, SASand safely adopted as part of a multimodal analgesic strategy in the postoperative period.
At the conclusion of the session, the presenters offered a number of resources for self-education including ACOG notifications (https://www.acog.org/myacog/communication-preferences ), Society for Maternal-Fetal Medicine updates(https://www.smfm.org/publications); and the CDC “Health Matters for Women” newsletter (https://www.cdc.gov/women/newsletter/index.htm)
Reference
Isaacs C, Leininger WM.Our annual booster shot: clinical updates from ACOG-SASGOG. 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. May 7, 2022. San Diego, California.
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
Buprenorphine use in pregnancy linked to decreased fetal breathing movements
May 18th 2024According to a poster presented at ACOG 2024, use of the synthetic opioid buprenorphine depressed fetal breathing in biophysical profile assessments, but had no significant impact on other factors like amniotic fluid index or fetal tone.
Read More
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Identifying gaps in syphilis treatment and prenatal care among pregnant individuals
May 17th 2024Preventing congenital syphilis comes down to quick diagnosis and treatment of the infection in pregnancy, and the number of missed opportunities to do so in the United States continues to grow.
Read More